1. Home
  2. EDSA vs SISI Comparison

EDSA vs SISI Comparison

Compare EDSA & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • SISI
  • Stock Information
  • Founded
  • EDSA 2015
  • SISI 1997
  • Country
  • EDSA Canada
  • SISI China
  • Employees
  • EDSA N/A
  • SISI N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • SISI Medicinal Chemicals and Botanical Products
  • Sector
  • EDSA Health Care
  • SISI Health Care
  • Exchange
  • EDSA Nasdaq
  • SISI Nasdaq
  • Market Cap
  • EDSA 6.2M
  • SISI 5.9M
  • IPO Year
  • EDSA N/A
  • SISI 2016
  • Fundamental
  • Price
  • EDSA $2.43
  • SISI $1.24
  • Analyst Decision
  • EDSA Strong Buy
  • SISI
  • Analyst Count
  • EDSA 1
  • SISI 0
  • Target Price
  • EDSA $21.00
  • SISI N/A
  • AVG Volume (30 Days)
  • EDSA 5.9M
  • SISI 69.5K
  • Earning Date
  • EDSA 02-14-2025
  • SISI 02-14-2025
  • Dividend Yield
  • EDSA N/A
  • SISI N/A
  • EPS Growth
  • EDSA N/A
  • SISI N/A
  • EPS
  • EDSA N/A
  • SISI N/A
  • Revenue
  • EDSA N/A
  • SISI $11,072,553.00
  • Revenue This Year
  • EDSA N/A
  • SISI N/A
  • Revenue Next Year
  • EDSA N/A
  • SISI N/A
  • P/E Ratio
  • EDSA N/A
  • SISI N/A
  • Revenue Growth
  • EDSA N/A
  • SISI 145.88
  • 52 Week Low
  • EDSA $1.55
  • SISI $1.08
  • 52 Week High
  • EDSA $5.59
  • SISI $117.65
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 56.54
  • SISI 38.76
  • Support Level
  • EDSA $2.30
  • SISI $1.19
  • Resistance Level
  • EDSA $4.49
  • SISI $1.32
  • Average True Range (ATR)
  • EDSA 0.30
  • SISI 0.08
  • MACD
  • EDSA 0.05
  • SISI 0.01
  • Stochastic Oscillator
  • EDSA 22.56
  • SISI 37.38

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About SISI Shineco Inc.

Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.

Share on Social Networks: